Historical source coverage
40 selected records with a cited source date in 2014. This archive is selective and does not imply continuous monitoring or complete historical coverage.
Regulatory · Liraglutide
The official Drugs@FDA dataset lists original submission 1 for NDA 206321 with status AP dated 2014-12-23, and names liraglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials · Bremelanotide
PeptideScanner retained ClinicalTrials.gov record NCT01382719 at 2026-07-30T21:54:46.551Z. Its registry update date was 2014-12-18, and PeptideScanner's reviewed identity mapping was bremelanotide.
Source: ClinicalTrials.gov ↗
Clinical trials · Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT01507389 at 2026-07-30T21:54:46.547Z. Its registry update date was 2014-12-09, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Clinical trials · Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT02305069 at 2026-07-30T21:54:46.552Z. Its registry update date was 2014-12-02, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Clinical trials · Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT00412061 at 2026-07-30T21:54:46.554Z. Its registry update date was 2014-11-21, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Literature metadata · Bremelanotide
PeptideScanner retained PubMed bibliographic metadata for PMID 14963471 at 2026-07-30T21:55:37.950Z. PubMed recorded a metadata revision date of 2014-11-20 and an Entrez history date of 2004-02-14. PeptideScanner associated this retained record with the identity slug bremelanotide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata · Bremelanotide
PeptideScanner retained PubMed bibliographic metadata for PMID 15134289 at 2026-07-30T21:55:37.950Z. PubMed recorded a metadata revision date of 2014-11-20 and an Entrez history date of 2004-05-12. PeptideScanner associated this retained record with the identity slug bremelanotide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata · Elamipretide
PeptideScanner retained PubMed bibliographic metadata for PMID 17151329 at 2026-07-30T21:55:37.962Z. PubMed recorded a metadata revision date of 2014-11-20 and an Entrez history date of 2006-12-08. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Regulatory · Dulaglutide
DailyMed lists Structured Product Labeling version 5 for the reviewed Dulaglutide label family with a published date of 2014-10-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials · Dulaglutide
PeptideScanner retained ClinicalTrials.gov record NCT01524770 at 2026-07-30T21:54:46.539Z. Its registry update date was 2014-10-22, and PeptideScanner's reviewed identity mapping was dulaglutide.
Source: ClinicalTrials.gov ↗
Regulatory · Leuprolide
The Federal Register published notice 2014-23961, attributed to FDA and its parent HHS department, on 2014-10-08. Its official title is “Determination That LUPRON DEPOT (Leuprolide Acetate for Depot Suspension), Injectable 3.75 Milligrams/Vial Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.
Source: Federal Register via GovInfo ↗
Clinical trials · Dulaglutide
PeptideScanner retained ClinicalTrials.gov record NCT01432938 at 2026-07-30T21:54:46.558Z. Its registry update date was 2014-10-07, and PeptideScanner's reviewed identity mapping was dulaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials · Dulaglutide
PeptideScanner retained ClinicalTrials.gov record NCT01436201 at 2026-07-30T21:54:46.550Z. Its registry update date was 2014-10-07, and PeptideScanner's reviewed identity mapping was dulaglutide.
Source: ClinicalTrials.gov ↗
Regulatory · Dulaglutide
DailyMed lists Structured Product Labeling version 4 for the reviewed Dulaglutide label family with a published date of 2014-10-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials · Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT01166958 at 2026-07-30T21:54:46.558Z. Its registry update date was 2014-09-22, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Regulatory · Dulaglutide
The official Drugs@FDA dataset lists original submission 1 for BLA 125469 with status AP dated 2014-09-18, and names dulaglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials · Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT01270789 at 2026-07-30T21:54:46.538Z. Its registry update date was 2014-09-12, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Clinical trials · Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT01237197 at 2026-07-30T21:54:46.554Z. Its registry update date was 2014-09-12, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Regulatory · Leuprolide
The Federal Register published notice 2014-19713, attributed to FDA and its parent HHS department, on 2014-08-20. Its official title is “Determination That LUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension), Injectable 3.75 Milligrams/Vial and 7.5 Milligrams/Vial; and LUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension), Injectable 7.5 Milligrams/Vial and 7.5 Milligrams/Vial, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.
Source: Federal Register via GovInfo ↗
Literature metadata · Lanreotide
PeptideScanner retained PubMed bibliographic metadata for PMID 15003204 at 2026-07-30T21:55:37.950Z. PubMed recorded a metadata revision date of 2014-08-18 and an Entrez history date of 2004-03-09. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Regulatory · Liraglutide
The Federal Register published notice 2014-18304, attributed to FDA and its parent HHS department, on 2014-08-04. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.
Source: Federal Register via GovInfo ↗
Regulatory · Lanreotide
The Federal Register published notice 2014-17293, attributed to FDA and its parent HHS department, on 2014-07-23. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Lanreotide.
Source: Federal Register via GovInfo ↗
Regulatory · Linaclotide
DailyMed lists Structured Product Labeling version 7 for the reviewed Linaclotide label family with a published date of 2014-07-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Linaclotide
DailyMed lists Structured Product Labeling version 6 for the reviewed Linaclotide label family with a published date of 2014-07-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials · Lanreotide
PeptideScanner retained ClinicalTrials.gov record NCT01354405 at 2026-07-30T21:54:46.540Z. Its registry update date was 2014-07-09, and PeptideScanner's reviewed identity mapping was lanreotide.
Source: ClinicalTrials.gov ↗
Clinical trials · Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT01669291 at 2026-07-30T21:54:46.557Z. Its registry update date was 2014-06-04, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Clinical trials · Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT00521300 at 2026-07-30T21:54:46.544Z. Its registry update date was 2014-06-02, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Regulatory · Linaclotide
The Federal Register published notice 2014-11926, attributed to FDA and its parent HHS department, on 2014-05-23. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; LINZESS,” and PeptideScanner's exact reviewed identity mapping connects the document to Linaclotide.
Source: Federal Register via GovInfo ↗
Clinical trials · Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT01088529 at 2026-07-30T21:54:46.544Z. Its registry update date was 2014-05-15, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Clinical trials · Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT01160328 at 2026-07-30T21:54:46.559Z. Its registry update date was 2014-05-14, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Safety · Leuprolide
FDA's dated enforcement report D-1287-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020517 through exact openFDA application-number annotations.
Safety · Leuprolide
FDA's dated enforcement report D-1288-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020517 through exact openFDA application-number annotations.
Safety · Leuprolide
FDA's dated enforcement report D-1289-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020263 through exact openFDA application-number annotations.
Safety · Leuprolide
FDA's dated enforcement report D-1290-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020708 through exact openFDA application-number annotations.
Safety · Leuprolide
FDA's dated enforcement report D-1291-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020517 through exact openFDA application-number annotations.
Regulatory · Leuprolide + 1 more
The Federal Register published notice 2014-07330, attributed to FDA and its parent HHS department, on 2014-04-02. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.
Source: Federal Register via GovInfo ↗
Clinical trials · Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT01611571 at 2026-07-30T21:54:46.552Z. Its registry update date was 2014-03-04, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Clinical trials · Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT01550653 at 2026-07-30T21:54:46.545Z. Its registry update date was 2014-02-27, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Clinical trials · Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT01916265 at 2026-07-30T21:54:46.545Z. Its registry update date was 2014-02-05, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Clinical trials · Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00003124 at 2026-07-30T21:54:46.538Z. Its registry update date was 2014-01-06, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗